Greenwich LifeSciences, Inc. (NasdaqCM: GLSI)
Health Care · Biotechnology · US
$16.53
-2.65% today · +60.5% 1Y
Greenwich LifeSciences, Inc. (NasdaqCM: GLSI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $242.63M and employs 13 people.
Over the last twelve months the share price has gained 60.5%, trading between 7.78 and 34.10.
Tweenvest scores Greenwich LifeSciences, Inc. across four factors: quality 35/100, value 46/100. Its strongest factor is value.
GLSI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $242.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.58
- Dividend yield
- —
- Beta (5Y)
- 1.46
- 52-week high
- $34.10
- 52-week low
- $7.78
- Avg volume (3M)
- —
- Shares outstanding
- 14.68M
- Employees
- 13
- Next earnings
- —
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
- ISIN
- US3968791083
- Founded
- 2006
- Listed since
- Sep 25, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shandong Boan Biotechnology Co., Ltd.SEHK: 6955 | $245.84M | HK$3.10 | +2.31% |
| Acepodia, Inc.TPEX: 6976 | $244.38M | NT$13.40 | +4.69% |
| Oryzon Genomics S.A.BME: ORY | $243.20M | €2.68 | +1.13% |
| Polaris GroupTWSE: 6550 | $242.78M | NT$16.70 | -0.30% |
| Pyxis Oncology, Inc.NasdaqGS: PYXS | $242.50M | $2.03 | -5.14% |
| SillaJen, Inc.KOSDAQ: A215600 | $241.16M | ₩2,340.00 | -0.85% |
| MacroGenics, Inc.NasdaqGS: MGNX | $238.24M | $3.64 | -2.67% |
| Keros Therapeutics, Inc.NasdaqGM: KROS | $236.93M | $11.95 | +5.19% |
Figures last refreshed Oct 11, 2026.